Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.A. B. Warner, Ravi A. Madan, Melissa L. Abel et al.|Journal of Clinical Oncology|2026Cited by 0
Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.Melissa L. Abel, Ravi A. Madan, Esther Mena et al.|Journal of Clinical Oncology|2026Cited by 0